<60 years old | 60–69 years old | 70–79 years old | >80 years old | Total | |
Patients n | 679 | 1082 | 1191 | 529 | 3481 |
Sex | |||||
Male | 354 (52.1) | 609 (56.3) | 718 (60.3) | 337 (63.7) | 2018 (58.0) |
Ethnicity | |||||
Oceania | 492 (72.4) | 715 (66.1) | 722 (60.6) | 285 (53.9) | 2214 (63.6) |
NW Europe | 57 (8.4) | 191 (17.7) | 302 (25.4) | 148 (28.0) | 698 (20.1) |
SE Europe | 18 (2.6) | 58 (5.4) | 74 (6.2) | 54 (10.2) | 204 (5.9) |
North Africa/Middle East | 18 (2.6) | 21 (1.9) | 29 (2.4) | 12 (2.3) | 80 (2.3) |
SE Asia | 45 (6.6) | 42 (3.9) | 24 (2.0) | 9 (1.7) | 120 (3.4) |
NE Asia | 23 (3.4) | 20 (1.9) | 14 (1.2) | 9 (1.7) | 66 (1.9) |
South/Central Asia | 12 (1.8) | 14 (1.3) | 11 (0.9) | 9 (1.7) | 46 (1.3) |
Americas | 8 (1.2) | 12 (1.1) | 8 (0.7) | 1 (0.2) | 29 (0.8) |
Sub-Saharan Africa | 7 (1.0) | 8 (0.7) | 7 (0.6) | 2 (0.4) | 24 (0.7) |
ECOG | |||||
0 | 328 (48.2) | 437 (40.4) | 337 (28.3) | 108 (20.4) | 1210 (34.8) |
1 | 272 (40.0) | 458 (42.4) | 581 (48.8) | 237 (44.8) | 1548 (44.5) |
2 | 59 (8.7) | 125 (11.6) | 185 (15.5) | 105 (19.8) | 474 (13.6) |
3 | 18 (2.6) | 50 (4.6) | 80 (6.7) | 70 (13.2) | 218 (6.3) |
4 | 3 (0.4) | 11 (1.0) | 8 (0.7) | 9 (1.7) | 31 (0.9) |
Comorbidities | |||||
Respiratory | 57 (8.4) | 143 (13.2) | 192 (16.1) | 66 (12.5) | 458 (13.2) |
Diabetes | 45 (6.6) | 151 (14.0) | 260 (21.8) | 106 (20.0) | 562 (16.1) |
Renal | 6 (0.9) | 10 (0.9) | 32 (2.7) | 10 (1.9) | 58 (1.7) |
AMI | 22 (3.2) | 112 (10.4) | 216 (18.1) | 137 (25.9) | 487 (14.0) |
Comorbid cancer | 62 (9.1) | 185 (17.1) | 255 (21.4) | 119 (22.5) | 621 (17.8) |
Number of medical comorbidities | |||||
0 | 566 (83.2) | 741 (68.5) | 648 (54.4) | 282 (53.3) | 2237 (64.3) |
1 | 101 (14.9) | 274 (25.3) | 403 (33.8) | 186 (35.2) | 964 (27.7) |
2 | 10 (1.5) | 56 (5.2) | 125 (10.5) | 50 (9.5) | 241 (6.9) |
3 | 3 (0.4) | 10 (0.9) | 13 (1.1) | 11 (2.1) | 37 (1.1) |
4 | 0 (0.0) | 0 (0.0) | 2 (0.2) | 0 (0.0) | 2 (0.1) |
Stage | |||||
1 | 55 (8.1) | 130 (12.0) | 164 (13.8) | 65 (12.3) | 414 (11.9) |
2 | 55 (8.1) | 91 (8.4) | 118 (9.9) | 50 (9.5) | 314 (9.0) |
3 | 198 (29.1) | 313 (29.0) | 352 (29.6) | 140 (26.5) | 1003 (28.8) |
4 | 372 (54.7) | 547 (50.6) | 557 (46.8) | 274 (51.8) | 1750 (50.3) |
Histology | |||||
Squamous cell cancer | 93 (13.7) | 211 (19.5) | 300 (25.2) | 126 (23.8) | 730 (21.0) |
Adenocarcinoma | 426 (62.6) | 603 (55.8) | 619 (52.0) | 277 (52.4) | 1925 (55.3) |
Large cell cancer | 21 (3.1) | 18 (1.7) | 21 (1.8) | 10 (1.9) | 70 (2.0) |
NOS | 84 (12.4) | 140 (13.0) | 130 (10.9) | 70 (13.2) | 424 (12.2) |
SCLC | 46 (6.8) | 87 (8.0) | 100 (8.4) | 28 (5.3) | 261 (7.5) |
Miscellaneous | 10 (1.5) | 22 (2.0) | 21 (1.8) | 18 (3.4) | 71 (2.0) |
Cancer treatment | |||||
Radiotherapy | 372 (54.7) | 516 (47.7) | 582 (48.9) | 253 (47.8) | 1723 (49.5) |
Surgery | 177 (26.0) | 279 (25.8) | 294 (24.7) | 79 (14.9) | 829 (23.8) |
Chemotherapy | 489 (71.9) | 666 (61.6) | 626 (52.6) | 140 (26.5) | 1921 (55.2) |
Immunotherapy/TKI | 136 (20.0) | 156 (14.4) | 125 (10.5) | 50 (9.5) | 467 (13.4) |
Any cancer treatment | 634 (93.2) | 962 (89.0) | 1031 (86.6) | 380 (71.8) | 3007 (86.4) |
Palliative care referral | 190 (27.9) | 282 (26.1) | 355 (29.8) | 229 (43.3) | 1056 (30.3) |
Data are presented as n (%), unless otherwise stated. ECOG: Eastern Cooperative Oncology Group; AMI: acute myocardial infarction; NOS: not otherwise specified; SCLC: small cell lung cancer; TKI: tyrosine kinase inhibitors (targeted therapy).